Dermata Therapeutics, Inc.
NASDAQSnapshot as of 14 May 2026
DRMA heads into its May 14 earnings print with insiders deeply committed — and short sellers cooling off from a frenzied spring. The clearest signal in the data is insider conviction. The CEO, CFO, and a founder each…
DRMA enters the post-earnings session with a notable alignment: the CEO who spent $1 million buying shares in December is now watching the company he built beat Q1 estimates — and the short base that towered over the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DRMA — free to start on ORTEX.
Sign up for free →Open DRMA on ORTEX